FDAnews
www.fdanews.com/articles/102565-cougar-biotechnology-begins-cb3304-trial

Cougar Biotechnology Begins CB3304 Trial

December 26, 2007

Cougar Biotechnology has enrolled the first patient in a Phase I trial of CB3304, an orally active alkaloid derived from opium.

The open-label, dose-escalating trial will evaluate the safety and efficacy of CB3304 (noscapine) administered daily to patients with relapsed or refractory multiple myeloma, Cougar Biotechnology said.

The company licensed exclusive rights to the drug from Emory University in March 2004.